X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (81) 81
humans (75) 75
male (59) 59
female (57) 57
middle aged (55) 55
aged (51) 51
hematology (51) 51
adult (49) 49
life sciences (31) 31
aged, 80 and over (29) 29
oncology (28) 28
chemotherapy (22) 22
retrospective studies (22) 22
cancer (20) 20
treatment outcome (20) 20
disease-free survival (18) 18
rituximab (17) 17
analysis (16) 16
abridged index medicus (14) 14
risk factors (14) 14
young adult (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
follow-up studies (13) 13
lymphoma (13) 13
prospective studies (13) 13
survival (13) 13
human health and pathology (12) 12
prognosis (12) 12
survival rate (12) 12
lymphomas (11) 11
[ sdv.can ] life sciences [q-bio]/cancer (10) 10
adolescent (10) 10
diagnosis (10) 10
hemic and lymphatic diseases (10) 10
non-hodgkins-lymphoma (10) 10
remission induction (10) 10
combined modality therapy (9) 9
leukemia (9) 9
patients (9) 9
recurrence (9) 9
research (9) 9
[sdv.can]life sciences [q-bio]/cancer (8) 8
efficacy (8) 8
medical research (8) 8
neoplasm staging (8) 8
therapy (8) 8
trial (8) 8
acute myeloid leukemia (7) 7
antineoplastic agents - therapeutic use (7) 7
pharmacology & pharmacy (7) 7
progression-free survival (7) 7
transplantation (7) 7
transplantation, autologous (7) 7
[sdv]life sciences [q-bio] (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
article (6) 6
b-cell lymphoma (6) 6
care and treatment (6) 6
classification (6) 6
cyclophosphamide (6) 6
disease (6) 6
ghana (6) 6
health aspects (6) 6
high-dose methotrexate (6) 6
immune system diseases (6) 6
immunology (6) 6
infectious diseases (6) 6
management (6) 6
mds (6) 6
medicine & public health (6) 6
medicine, experimental (6) 6
medicine, general & internal (6) 6
myelodysplastic syndromes (6) 6
primary cns lymphoma (6) 6
risk (6) 6
stem cell transplantation (6) 6
survival analysis (6) 6
time factors (6) 6
age factors (5) 5
anemia (5) 5
antibodies, monoclonal, murine-derived - administration & dosage (5) 5
antimetabolites, antineoplastic - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
apoptosis (5) 5
bone marrow (5) 5
cytarabine - administration & dosage (5) 5
drug administration schedule (5) 5
expression (5) 5
france (5) 5
hematology, oncology and palliative medicine (5) 5
high-dose therapy (5) 5
interferon (5) 5
kaplan-meier estimate (5) 5
methotrexate (5) 5
multicenter (5) 5
pharmacokinetics (5) 5
safety (5) 5
[ sdv.mhep.hem ] life sciences [q-bio]/human health and pathology/hematology (4) 4
antimetabolites, antineoplastic - administration & dosage (4) 4
antimitotic agents (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 09/2017, Volume 12, Issue 9, p. e0185303
Introduction Plasmodium falciparum induced antibodies are key components of anti-malarial immunity in malaria endemic areas, but their antigen targets can be... 
ERYTHROCYTE-BINDING ANTIGEN-175 | APICAL MEMBRANE ANTIGEN-1 | VACCINE CANDIDATE | PROTECTION | CLINICAL MALARIA | ACQUIRED-IMMUNITY | MULTIDISCIPLINARY SCIENCES | PLASMODIUM-FALCIPARUM ANTIGENS | MEROZOITE ANTIGENS | SEROLOGICAL MARKERS | HETEROLOGOUS STRAINS | Antibody Specificity | Antigens, Protozoan - immunology | Humans | Child, Preschool | Infant | Male | Plasmodium falciparum - immunology | Protozoan Proteins - genetics | Malaria, Falciparum - transmission | Antibodies, Protozoan - blood | Plasmodium falciparum - genetics | Malaria, Falciparum - epidemiology | Immunoassay - methods | Female | Antigens, Protozoan - genetics | Seasons | Child | Amino Acid Sequence | Membrane Proteins - genetics | Membrane Proteins - immunology | Ghana - epidemiology | Cross Reactions | Animals | Malaria, Falciparum - immunology | Longitudinal Studies | Protozoan Proteins - immunology | Cohort Studies | Measurement | Viral antibodies | Disease transmission | Malaria | Distribution | Antibodies | Physiological aspects | Development and progression | Research | Multiplexing | Vector-borne diseases | Health sciences | Medical research | Antigens | Parasitology | Immunoglobulins | Health services | Erythrocytes | Biochemistry | Infections | Parasites | Immunity | Proteins | Studies | Immunology | Trends | Children | Molecular biology
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5509 - 5509
Abstract Introduction Moderate anemia affects a substantial fraction of the elderly population and blood smear analysis can help to guide towards a diagnosis... 
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 747 - 757
Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a... 
SURVIVAL | MAJOR MOLECULAR RESPONSE | TREATMENT-FREE REMISSION | ONCOLOGY | IMATINIB DISCONTINUATION | DISEASE | FOLLOW-UP | DASATINIB | WITHDRAWAL SYNDROME | NILOTINIB | PHASE-2 TRIAL | Predictive Value of Tests | Prospective Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Clinical Decision-Making | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Polymerase Chain Reaction | Adult | Female | Biomarkers, Tumor - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Drug Administration Schedule | Risk Assessment | Europe | Risk Factors | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Progression-Free Survival | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Antimitotic agents | Tyrosine | Antineoplastic agents | Analysis | Life Sciences | Hematology | Human health and pathology | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2011, Volume 29, Issue 23, pp. 3194 - 3200
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 1845 - 1845
Abstract Background: Therapeutic guidelines in essential thrombocytemia (ET) are based on established criteria, ie. age more than 60 years, history of... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5351 - 5351
Abstract Introduction Extranodal NK/T-cell lymphoma (ENKTL) is a rare disease; in Western countries it represents less than 1% of all Non-Hodgkin lymphoma.... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 1, pp. 104 - 110
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 19, pp. 1916 - 1927
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2302 - 2302
Abstract Introduction: Idelalisib (IDELA), the first PI3K delta inhibitor, is indicated in Europe in combination with rituximab (R) or ofatumumab for the... 
Journal Article
Haematologica, ISSN 0390-6078, 07/2012, Volume 97, Issue 7, pp. 1085 - 1091
Journal Article